OFIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Orthofix Medical Inc. is not a strong buy at this moment for a beginner investor with a long-term strategy. The company's financial performance shows modest revenue growth but significant declines in net income and EPS. The technical indicators are neutral, and there are no strong proprietary trading signals or significant positive catalysts to justify immediate action. Holding or waiting for clearer growth signals may be more prudent.
The MACD histogram is positive but contracting, indicating a potential weakening of upward momentum. RSI is neutral at 44.456, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 13.225, with resistance at 13.899 and support at 12.551.
The company reported a 3% YoY increase in Q4 2025 net sales and an optimistic 2026 sales outlook of $850-$860 million. Gross margin improved by 4.03% YoY.
Insider and hedge fund trading trends are neutral, and there is no significant congressional trading activity.
In Q4 2025, revenue increased by 1.97% YoY to $219.91 million. However, net income dropped significantly to -$2.22 million, and EPS fell to -$0.06. Gross margin improved to 69.7%, up 4.03% YoY.
Barrington lowered the price target to $17 from $18 but maintained an Outperform rating, citing solid Q4 results but a delayed EBITDA margin target. TD Cowen initiated coverage with a Hold rating and a $14 price target, noting ongoing efforts to improve profitability but a lack of top-line acceleration visibility until late 2026.
